Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05170009 · ClinicalTrials.gov registry record · Phase 2
Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05170009 is a Phase 2 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 2 participants.
The verdict
NCT05170009, a Phase 2 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. Although there are no data about this treatment option currently available, the investigator hypothesizes that combination therapy may be more effective in clearing influenza virus infection and decreasing the rate of emergence of resistant influenza in immunocompromised human hosts.
Interventions
- DRUG Placebo
- DRUG Baloxavir Marboxil
- DRUG Oseltamivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05170009
The ClinicalTrials.gov registry entry for NCT05170009 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05170009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05170009 about?
NCT05170009 is a clinical study titled "Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza". This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. Although there are no data about this treatment option currently a...
What is the current status of trial NCT05170009?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-04-22. Estimated completion is 2024-02-07.
What interventions are being tested in trial NCT05170009?
The interventions under investigation include: Placebo (DRUG), Baloxavir Marboxil (DRUG), Oseltamivir (DRUG).
Who is sponsoring clinical trial NCT05170009?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.